Weight does not simply snap back when patients stop Ozempic and similar GLP-1 drugs, according to a new Cleveland Clinic analysis of almost eight thousand records from Ohio and Florida. The dataset tracks people who discontinued GLP-1 prescriptions and then stayed in structured obesity care programs.
Researchers report that many patients did regain some weight, but the pattern depended heavily on follow-up treatment. Those who continued medical nutrition therapy, anti-obesity medications, or bariatric follow-up kept a substantial share of their prior weight loss. Patients who dropped out of obesity care showed larger rebounds on the scale.
The analysis highlights that GLP-1 agonists are one component of a chronic disease strategy, not a standalone fix. Ongoing management of energy balance, including diet, physical activity, and behavioral counseling, appeared to stabilize body mass index trajectories after drug discontinuation. For health systems, the findings reinforce obesity as a long-term care pathway rather than a short prescription cycle.
